High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells

FEBS Open Bio

Volumn 6, Issue 3, 2016, Pages 190-199

  Kawaguchi, Koichiro ^a   Senga, Shogo ^a   Kubota, Chiaki ^a   Kawamura, Yuki ^a   Ke, Youqiang ^b   Fujii, Hiroshi ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Colorectal cancer; FABP5; Fatty acid; Fatty acid binding proteins; Lipid metabolism; Metastasis

Indexed keywords

FATTY ACID BINDING PROTEIN; LONG CHAIN FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

EID: 84959479367     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1002/2211-5463.12031     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Markowitz SD and Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361, 2449-2460.
3. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6, 479-507.
4. Morgan EA, Forootan SS, Adamson J, Foster CS, Fujii H, Igarashi M, Beesley C, Smith PH and Ke Y (2008) Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression. Int J Oncol 32, 767-775.
5. Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H, Rudland PS, Smith PH and Ke Y (2003) High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 22, 2739-2749.
6. Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, Fujii H, Smith PH and Ke Y (2001) Human cutaneous fatty acid-binding protein induces metastasis by up-regulating the expression of vascular endothelial growth factor gene in rat Rama 37 model cells. Cancer Res 61, 4357-4364.
7. Jing C, Beesley C, Foster CS, Rudland PS, Fujii H, Ono T, Chen H, Smith PH and Ke Y (2000) Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res 60, 2390-2398.
8. Bao Z, Malki MI, Forootan SS, Adamson J, Forootan FS, Chen D, Foster CS, Rudland PS and Ke Y (2013) A novel cutaneous Fatty Acid-binding protein-related signaling pathway leading to malignant progression in prostate cancer cells. Genes Cancer 4, 297-314.
9. Forootan FS, Forootan SS, Malki MI, Chen D, Li G, Lin K, Rudland PS, Foster CS and Ke Y (2014) The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer. Int J Oncol 44, 265-275.
10. Fang LY, Wong TY, Chiang WF and Chen YL (2010) Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. J Oral Pathol Med 39, 342-348.
11. Jeong CY, Hah YS, Cho BI, Lee SM, Joo YT, Jung EJ, Jeong SH, Lee YJ, Choi SK, Ha WS et al. (2012) Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma. Oncol Rep 28, 1283-1292.
12. Sinha P, Hütter G, Köttgen E, Dietel M, Schadendorf D and Lage H (1999) Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis 20, 2952-2960.
13. Chen R, Feng C and Xu Y (2011) Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res 39, 533-540.
14. Liu RZ, Graham K, Glubrecht DD, Germain DR, Mackey JR and Godbout R (2011) Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol 178, 997-1008.
15. Powell CA, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro C, Shilo K and Ganju RK (2015) Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget 6, 6373-6385.
16. Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K and Hirohashi S (2005) Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics 5, 1411-1422.
17. Koshiyama A, Ichibangase T and Imai K (2013) Comprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate. Biomed Chromatogr 27, 440-450.
18. Smathers RL and Petersen DR (2011) The human fatty acid-binding protein family: evolutionary divergences and functions. Hum Genomics 5, 170-191.
19. Zimmerman AW and Veerkamp JH (2002) New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 59, 1096-1116.
20. Storch J and Corsico B (2008) The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 28, 73-95.
21. Storch J and Thumser AE (2010) Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 285, 32679-32683.
22. Currie E, Schulze A, Zechner R, Walther TC and Farese RV (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18, 153-161.
23. Santos CR and Schulze A (2012) Lipid metabolism in cancer. FEBS J 279, 2610-2623.
24. Watanabe R, Fujii H, Yamamoto A, Hashimoto T, Kameda K, Ito M and Ono T (1997) Immunohistochemical distribution of cutaneous fatty acid-binding protein in human skin. J Dermatol Sci 16, 17-22.
25. Ohmachi T, Inoue H, Mimori K, Tanaka F, Sasaki A, Kanda T, Fujii H, Yanaga K and Mori M (2006) Fatty acid binding protein 6 is overexpressed in colorectal cancer. Clin Cancer Res 12, 5090-5095.
26. Fang C, Dean J and Smith JW (2007) A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res 67, 9039-9046.
27. Zirvi KA, Najjar TA and Slomiany BL (1993) Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice. Cancer Lett 72, 39-44.
28. Hamada K, Monnai M, Kawai K, Nishime C, Kito C, Miyazaki N, Ohnishi Y, Nakamura M and Suemizu H (2008) Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. Int J Oncol 32, 153-159.
29. Sherr CJ and Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13, 1501-1512.
30. Seoane J, Le HV and Massagué J (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729-734.
31. Schulze A and Harris AL (2012) How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364-373.
32. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW and Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140, 49-61.
33. Kannan-Thulasiraman P, Seachrist DD, Mahabeleshwar GH, Jain MK and Noy N (2010) Fatty acid-binding protein 5 and PPARbeta/delta are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. J Biol Chem 285, 19106-19115.
34. Morgan E, Kannan-Thulasiraman P and Noy N (2010) Involvement of fatty acid binding protein 5 and PPARβ/δ in prostate cancer cell growth. PPAR Res 2010, 234629.
35. Levi L, Lobo G, Doud MK, von Lintig J, Seachrist D, Tochtrop GP and Noy N (2013) Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res 73, 4770-4780.
36. Targett-Adams P, McElwee MJ, Ehrenborg E, Gustafsson MC, Palmer CN and McLauchlan J (2005) A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochim Biophys Acta 1728, 95-104.
37. Di-Poï N, Tan NS, Michalik L, Wahli W and Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10, 721-733.
38. Borland MG, Khozoie C, Albrecht PP, Zhu B, Lee C, Lahoti TS, Gonzalez FJ and Peters JM (2011) Stable over-expression of PPARβ/δ and PPARγ to examine receptor signaling in human HaCaT keratinocytes. Cell Signal 23, 2039-2050.
39. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ and Peters JM (2006) Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res 66, 4394-4401.
40. Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN, Willson TM, Sharma AK, Amin S, Gonzalez FJ and Peters JM (2007) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28, 2641-2649.
41. Yang L, Zhou J, Ma Q, Wang C, Chen K, Meng W, Yu Y, Zhou Z and Sun X (2013) Knockdown of PPARδ gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model. PLoS One 8, e60715.
42. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, Sharma AK, Amin S, Murray IA, Anderson CR et al. (2010) Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol 78, 419-430.